Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: A pooled subanalysis from ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT) - 03/08/18
Kristian Reich, SCIderm Research Institute and Dermatologikum Hamburg; Alice B. Gottlieb, New York Medical College; Andrew Blauvelt, Oregon Medical Research Center; Howard Sofen, David Geffen School of Medicine at UCLA; Jolanta Weglowska, Niepubliczny Zaklad Opieki Zdrowotney multiMedica; Matthias Augustin, University Medical Center Hamburg-Eppendorf; Yves Poulin, Centre de Recherche Dermatologique de Quebec Metropolitain; Janice Drewof Danil Burge, Dermira, Inc.; Luke Peterson, UCB BioSciences, Inc.; Robert Rolleri, UCB BioSciences, Inc.; Craig Leonardi, Central Dermatology
Le texte complet de cet article est disponible en PDF.| Commercial support: Dermira, Inc. Dermira and UCB are in a strategic collaboration to evaluate the efficacy and safety of certolizumab pegol in the treatment of moderate-to-severe plaque psoriasis. Medical writing support provided by Prescott Medical Communications Group. |
Vol 79 - N° 3S1
P. AB66 - septembre 2018 Retour au numéro
Article précédent
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: A case of a neurologic disease with a skin-deep diagnosis
- Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: A pooled subanalysis of ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?